MA26964A1 - Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase. - Google Patents

Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.

Info

Publication number
MA26964A1
MA26964A1 MA27165A MA27165A MA26964A1 MA 26964 A1 MA26964 A1 MA 26964A1 MA 27165 A MA27165 A MA 27165A MA 27165 A MA27165 A MA 27165A MA 26964 A1 MA26964 A1 MA 26964A1
Authority
MA
Morocco
Prior art keywords
diabetic
combinations
association
dehydrogenase inhibitors
gaba
Prior art date
Application number
MA27165A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26964A1 publication Critical patent/MA26964A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 30 Novembre 2000 60/250,069 Voir en annexe le titre de l'invention et le texte de l'abrégé Association d'agonistes de GABA et d'inhibiteurs de sorbitol-déshydrogénase L'invention concerne des compositions pharma??ceutiques comprenant des associations d'un agoniste de GABA, d'un de ses précurseurs médicamenteux ou d'un sel pharmaceutiquement acceptable dudit agoniste de GABA ou dudit précurseur médicamenteux, et d'un SDI, d'un de ses précurseurs médicamenteux, ou d'un sel pharmaceutiquement acceptable dudit SDI ou dudit précurseur médicamenteux, des kits contenant ces associations, et des méthodes d'utilisation de ces associations pour le traitement de mammifères, y compris l'homme, souffrant de complications diabétiques, telles que la neuropathie diabétique, la néphropathie diabétique, la myocardiopathie diabétique, la rétinopathie diabétique, la microangiopathie diabétique, la macroangiopathie diabétique, les catarates ou les ulcères des pieds. Application : utilisation des compositions pour le traitement des complications du diabète chez des mammifères, y compris l'homme.
MA27165A 2000-11-30 2003-05-20 Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase. MA26964A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
MA26964A1 true MA26964A1 (fr) 2004-12-20

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27165A MA26964A1 (fr) 2000-11-30 2003-05-20 Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.

Country Status (38)

Country Link
US (1) US6544998B2 (fr)
EP (1) EP1337271B1 (fr)
JP (1) JP2004514699A (fr)
KR (1) KR20030059290A (fr)
CN (1) CN1477975A (fr)
AP (1) AP2001002360A0 (fr)
AR (1) AR031431A1 (fr)
AT (1) ATE281181T1 (fr)
AU (1) AU2002215159A1 (fr)
BG (1) BG107774A (fr)
BR (1) BR0115783A (fr)
CA (1) CA2430298A1 (fr)
CR (1) CR6964A (fr)
CZ (1) CZ20031399A3 (fr)
DE (1) DE60106968T2 (fr)
DO (1) DOP2001000289A (fr)
EA (1) EA200300432A1 (fr)
EC (1) ECSP034624A (fr)
EE (1) EE200300248A (fr)
ES (1) ES2230378T3 (fr)
HR (1) HRP20030420A2 (fr)
HU (1) HUP0302160A3 (fr)
IL (1) IL155704A0 (fr)
IS (1) IS6786A (fr)
MA (1) MA26964A1 (fr)
MX (1) MXPA03004870A (fr)
NO (1) NO20032441L (fr)
OA (1) OA12534A (fr)
PA (1) PA8534101A1 (fr)
PE (1) PE20020597A1 (fr)
PL (1) PL365927A1 (fr)
PT (1) PT1337271E (fr)
SK (1) SK6192003A3 (fr)
SV (1) SV2003000751A (fr)
TN (1) TNSN01169A1 (fr)
UY (1) UY27042A1 (fr)
WO (1) WO2002043762A2 (fr)
ZA (1) ZA200303381B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
SK286227B6 (sk) 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
WO2005097079A2 (fr) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Formes galeniques pharmaceutiques a liberation immediate et/ou controlee renfermant un agoniste du recepteur gabab
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
WO2006088075A1 (fr) 2005-02-17 2006-08-24 Astellas Pharma Inc. Derive d’ester de 1-carboxylate heterocyclique azote non-aromatique de pyridyle
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
PE20130325A1 (es) * 2007-04-27 2013-03-18 Purdue Pharma Lp Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
AU2008310114B2 (en) * 2007-10-09 2014-01-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
WO2012050907A2 (fr) * 2010-09-28 2012-04-19 The Regents Of The University Of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
MX354015B (es) 2011-06-22 2018-02-08 Shionogi & Co Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos.
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
IT1147087B (it) 1979-06-01 1986-11-19 Wellcome Found Nuovi preparati farmaceutici per il trattamento dei disordini del sistema nervoso centrale e procedimento per la loro preparazione
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JP2789134B2 (ja) * 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
PT1041068E (pt) * 1999-04-01 2004-07-30 Pfizer Prod Inc Compostos para o tratamento e prevencao de complicacoes diabeticas
JP3581103B2 (ja) * 1999-04-01 2004-10-27 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン

Also Published As

Publication number Publication date
IL155704A0 (en) 2003-11-23
PA8534101A1 (es) 2002-10-31
NO20032441D0 (no) 2003-05-28
EE200300248A (et) 2003-10-15
ECSP034624A (es) 2003-07-25
CN1477975A (zh) 2004-02-25
DOP2001000289A (es) 2003-02-15
EP1337271B1 (fr) 2004-11-03
SK6192003A3 (en) 2004-07-07
CR6964A (es) 2004-02-02
CZ20031399A3 (cs) 2004-04-14
UY27042A1 (es) 2002-07-31
ATE281181T1 (de) 2004-11-15
TNSN01169A1 (fr) 2005-11-10
JP2004514699A (ja) 2004-05-20
WO2002043762A3 (fr) 2003-03-13
HUP0302160A2 (hu) 2003-11-28
DE60106968D1 (de) 2004-12-09
DE60106968T2 (de) 2005-11-03
HRP20030420A2 (en) 2004-08-31
WO2002043762A2 (fr) 2002-06-06
EA200300432A1 (ru) 2003-10-30
EP1337271A2 (fr) 2003-08-27
NO20032441L (no) 2003-07-03
CA2430298A1 (fr) 2002-06-06
BR0115783A (pt) 2003-09-16
US6544998B2 (en) 2003-04-08
AU2002215159A1 (en) 2002-06-11
KR20030059290A (ko) 2003-07-07
SV2003000751A (es) 2003-01-13
ES2230378T3 (es) 2005-05-01
ZA200303381B (en) 2004-04-30
IS6786A (is) 2003-04-14
OA12534A (en) 2006-06-05
AP2001002360A0 (en) 2001-12-31
US20020091128A1 (en) 2002-07-11
HUP0302160A3 (en) 2005-05-30
MXPA03004870A (es) 2003-08-19
AR031431A1 (es) 2003-09-24
PL365927A1 (en) 2005-01-10
BG107774A (en) 2004-01-30
PT1337271E (pt) 2005-01-31
PE20020597A1 (es) 2002-07-08

Similar Documents

Publication Publication Date Title
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
MA26965A1 (fr) Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
US11491172B2 (en) Compositions and methods of potentiating antimicrobials
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
EA200870154A1 (ru) Лекарственное средство для местного применения
Rettori et al. Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
SI1656122T2 (sl) Transdermalni farmacevtski pripravki s kombinacijami učinkovin za zdravljenje Parkinsonove bolezni
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
UA88938C2 (ru) Твердые фармацевтические формы для перорального введения, которые содержат ривароксабан, с модифицированным высвобождением
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
SE0102055D0 (sv) New Compounds
Whitaker et al. Bacteriostatic effect of simvastatin on selected oral streptococci in vitro
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
WO2005004915A3 (fr) Compositions contenant meloxicam
EA200870153A1 (ru) Композиция и способ ее использования
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque